35 results on '"Murtaza, Muhammed"'
Search Results
2. Association of Neighborhood Disadvantage with Short- and Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma
- Author
-
Marcinak, Clayton T., Praska, Corinne E., Vidri, Roberto J., Taylor, Amy K., Krebsbach, John K., Ahmed, Kaleem S., LoConte, Noelle K., Varley, Patrick R., Afshar, Majid, Weber, Sharon M., Abbott, Daniel E., Mathew, Jomol, Murtaza, Muhammed, Burkard, Mark E., Churpek, Matthew M., and Zafar, Syed Nabeel
- Published
- 2024
- Full Text
- View/download PDF
3. Colon Cancer Survival Among South Asian Americans: A Cross-Sectional Analysis of a National Dataset
- Author
-
Ahmed, Kaleem S., Marcinak, Clayton T., LoConte, Noelle K., Krebsbach, John K., Virani, Sehar S., Schiefelbein, Andrea M., Varley, Patrick, Walker, Margaret, Ghias, Kulsoom, Murtaza, Muhammed, and Zafar, Syed Nabeel
- Published
- 2024
- Full Text
- View/download PDF
4. Genomic Profiling and Liquid Biopsies for Breast Cancer
- Author
-
Marcinak, Clayton T., Murtaza, Muhammed, and Wilke, Lee G.
- Published
- 2023
- Full Text
- View/download PDF
5. Feasibility of circulating tumor DNA analysis in dogs with naturally occurring malignant and benign splenic lesions
- Author
-
Favaro, Patricia Filippsen, Stewart, Samuel D., McDonald, Bradon R., Cawley, Jacob, Contente-Cuomo, Tania, Wong, Shukmei, Hendricks, William P. D., Trent, Jeffrey M., Khanna, Chand, and Murtaza, Muhammed
- Published
- 2022
- Full Text
- View/download PDF
6. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
- Author
-
Chehrazi-Raffle, Alexander, Muddasani, Ramya, Dizman, Nazli, Hsu, JoAnn, Meza, Luis, Zengin, Zeynep B., Malhotra, Jasnoor, Chawla, Neal, Dorff, Tanya, Contente-Cuomo, Tania, Dinwiddie, Devin, McDonald, Bradon R., McDaniel, Timothy, Trent, Jeffrey M., Baehner, Frederick L., Murtaza, Muhammed, and Pal, Sumanta K.
- Published
- 2023
- Full Text
- View/download PDF
7. Primary glomus tumour of the pituitary gland: diagnostic challenges of a rare and potentially aggressive neoplasm
- Author
-
Quah, Boon Leong, Donofrio, Carmine Antonio, La Rosa, Stefano, Brouland, Jean-Philippe, Cossu, Giulia, Djoukhadar, Ibrahim, Mayers, Helen, Shenjere, Patrick, Pereira, Marta, Pathmanaban, Omar N., Murtaza, Muhammed O., Gattamaneni, Rao, Roncaroli, Federico, and Karabatsou, Konstantina
- Published
- 2021
- Full Text
- View/download PDF
8. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
- Author
-
De Mattos-Arruda, Leticia, Sammut, Stephen-John, Ross, Edith M., Bashford-Rogers, Rachael, Greenstein, Erez, Markus, Havell, Morganella, Sandro, Teng, Yvonne, Maruvka, Yosef, Pereira, Bernard, Rueda, Oscar M., Chin, Suet-Feung, Contente-Cuomo, Tania, Mayor, Regina, Arias, Alexandra, Ali, H. Raza, Cope, Wei, Tiezzi, Daniel, Dariush, Aliakbar, Dias Amarante, Tauanne, Reshef, Dan, Ciriaco, Nikaoly, Martinez-Saez, Elena, Peg, Vicente, Ramon y Cajal, Santiago, Cortes, Javier, Vassiliou, George, Getz, Gad, Nik-Zainal, Serena, Murtaza, Muhammed, Friedman, Nir, Markowetz, Florian, Seoane, Joan, and Caldas, Carlos
- Published
- 2019
- Full Text
- View/download PDF
9. Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis
- Author
-
Perdigones, Nieves and Murtaza, Muhammed
- Published
- 2017
- Full Text
- View/download PDF
10. Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
- Author
-
Tsui, Dana Wai Yi, Murtaza, Muhammed, Wong, Alvin Seng Cheong, Rueda, Oscar M, Smith, Christopher G, Chandrananda, Dineika, Soo, Ross A, Lim, Hong Liang, Goh, Boon Cher, Caldas, Carlos, Forshew, Tim, Gale, Davina, Liu, Wei, Morris, James, Marass, Francesco, Eisen, Tim, Chin, Tan Min, and Rosenfeld, Nitzan
- Published
- 2018
- Full Text
- View/download PDF
11. The Pakistan Risk of Myocardial Infarction Study: A Resource for the Study of Genetic, Lifestyle and Other Determinants of Myocardial Infarction in South Asia
- Author
-
Saleheen, Danish, Zaidi, Moazzam, Rasheed, Asif, Ahmad, Usman, Hakeem, Abdul, Murtaza, Muhammed, Kayani, Waleed, Faruqui, Azhar, Kundi, Assadullah, Zaman, Khan Shah, Yaqoob, Zia, Cheema, Liaquat Ali, Samad, Abdus, Rasheed, Syed Zahed, Mallick, Nadeem Hayat, Azhar, Muhammad, Jooma, Rashid, Gardezi, Ali Raza, Memon, Nazir, Ghaffar, Abdul, Fazal-ur-Rehman, Khan, Nadir, Shah, Nabi, Shah, Asad Ali, Samuel, Maria, Hanif, Farina, Yameen, Madiha, Naz, Sobia, Sultana, Aisha, Nazir, Aisha, Raza, Shehzad, Shazad, Muhammad, Nasim, Sana, Javed, Muhammad Ahsan, Ali, Syed Saadat, Jafree, Mehmood, Nisar, Muhammad Imran, Daood, Muhammad Salman, Hussain, Altaf, Sarwar, Nadeem, Kamal, Ayeesha, Deloukas, Panos, Ishaq, Muhammad, Frossard, Philippe, and Danesh, John
- Published
- 2009
- Full Text
- View/download PDF
12. Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height
- Author
-
Lanktree, Matthew B., Guo, Yiran, Murtaza, Muhammed, Glessner, Joseph T., Bailey, Swneke D., Onland-Moret, N. Charlotte, Lettre, Guillaume, Ongen, Halit, Rajagopalan, Ramakrishnan, Johnson, Toby, Shen, Haiqing, Nelson, Christopher P., Klopp, Norman, Baumert, Jens, Padmanabhan, Sandosh, Pankratz, Nathan, Pankow, James S., Shah, Sonia, Taylor, Kira, Barnard, John, Peters, Bas J., M. Maloney, Cliona, Lobmeyer, Maximilian T., Stanton, Alice, Zafarmand, M. Hadi, Romaine, Simon P.R., Mehta, Amar, van Iperen, Erik P.A., Gong, Yan, Price, Tom S., Smith, Erin N., Kim, Cecilia E., Li, Yun R., Asselbergs, Folkert W., Atwood, Larry D., Bailey, Kristian M., Bhatt, Deepak, Bauer, Florianne, Behr, Elijah R., Bhangale, Tushar, Boer, Jolanda M.A., Boehm, Bernhard O., Bradfield, Jonathan P., Brown, Morris, Braund, Peter S., Burton, Paul R., Carty, Cara, Chandrupatla, Hareesh R., Chen, Wei, Connell, John, Dalgeorgou, Chrysoula, Boer, Anthonius de, Drenos, Fotios, Elbers, Clara C., Fang, James C., Fox, Caroline S., Frackelton, Edward C., Fuchs, Barry, Furlong, Clement E., Gibson, Quince, Gieger, Christian, Goel, Anuj, Grobbee, Diederik E., Hastie, Claire, Howard, Philip J., Huang, Guan-Hua, Johnson, W. Craig, Li, Qing, Kleber, Marcus E., Klein, Barbara E.K., Klein, Ronald, Kooperberg, Charles, Ky, Bonnie, LaCroix, Andrea, Lanken, Paul, Lathrop, Mark, Li, Mingyao, Marshall, Vanessa, Melander, Olle, Mentch, Frank D., J. Meyer, Nuala, Monda, Keri L., Montpetit, Alexandre, Murugesan, Gurunathan, Nakayama, Karen, Nondahl, Dave, Onipinla, Abiodun, Rafelt, Suzanne, Newhouse, Stephen J., Otieno, F. George, Patel, Sanjey R., Putt, Mary E., Rodriguez, Santiago, Safa, Radwan N., Sawyer, Douglas B., Schreiner, Pamela J., Simpson, Claire, Sivapalaratnam, Suthesh, Srinivasan, Sathanur R., Suver, Christine, Swergold, Gary, Sweitzer, Nancy K., Thomas, Kelly A., Thorand, Barbara, Timpson, Nicholas J., Tischfield, Sam, Tobin, Martin, Tomaszweski, Maciej, Verschuren, W.M. Monique, Wallace, Chris, Winkelmann, Bernhard, Zhang, Haitao, Zheng, Dongling, Zhang, Li, Zmuda, Joseph M., Clarke, Robert, Balmforth, Anthony J., Danesh, John, Day, Ian N., Schork, Nicholas J., de Bakker, Paul I.W., Delles, Christian, Duggan, David, Hingorani, Aroon D., Hirschhorn, Joel N., Hofker, Marten H., Humphries, Steve E., Kivimaki, Mika, Lawlor, Debbie A., Kottke-Marchant, Kandice, Mega, Jessica L., Mitchell, Braxton D., Morrow, David A., Palmen, Jutta, Redline, Susan, Shields, Denis C., Shuldiner, Alan R., Sleiman, Patrick M., Smith, George Davey, Farrall, Martin, Jamshidi, Yalda, Christiani, David C., Casas, Juan P., Hall, Alistair S., Doevendans, Pieter A., D. Christie, Jason, Berenson, Gerald S., Murray, Sarah S., Illig, Thomas, Dorn, Gerald W., II, Cappola, Thomas P., Boerwinkle, Eric, Sever, Peter, Rader, Daniel J., Reilly, Muredach P., Caulfield, Mark, Talmud, Philippa J., Topol, Eric, Engert, James C., Wang, Kai, Dominiczak, Anna, Hamsten, Anders, Curtis, Sean P., Silverstein, Roy L., Lange, Leslie A., Sabatine, Marc S., Trip, Mieke, Saleheen, Danish, Peden, John F., Cruickshanks, Karen J., März, Winfried, O'Connell, Jeffrey R., Klungel, Olaf H., Wijmenga, Cisca, Maitland-van der Zee, Anke Hilse, Schadt, Eric E., Johnson, Julie A., Jarvik, Gail P., Papanicolaou, George J., Grant, Struan F.A., Munroe, Patricia B., North, Kari E., Samani, Nilesh J., Koenig, Wolfgang, Gaunt, Tom R., Anand, Sonia S., van der Schouw, Yvonne T., Soranzo, Nicole, FitzGerald, Garret A., Reiner, Alex, Hegele, Robert A., Hakonarson, Hakon, and Keating, Brendan J.
- Published
- 2011
- Full Text
- View/download PDF
13. Interaction between methadone and clarithromycin as the suspected cause of an opioid toxidrome.
- Author
-
Wallace, Blair, Edwardes, Daniel, Subbe, Christian, and Murtaza, Muhammed
- Published
- 2023
- Full Text
- View/download PDF
14. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- Author
-
Murtaza, Muhammed, Dawson, Sarah-Jane, Tsui, Dana W. Y., Gale, Davina, Forshew, Tim, Piskorz, Anna M., Parkinson, Christine, Chin, Suet-Feung, Kingsbury, Zoya, Wong, Alvin S. C., Marass, Francesco, Humphray, Sean, Hadfield, James, Bentley, David, Chin, Tan Min, Brenton, James D., Caldas, Carlos, and Rosenfeld, Nitzan
- Published
- 2013
- Full Text
- View/download PDF
15. Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- Author
-
Dawson, Sarah-Jane, Tsui, Dana W.Y., Murtaza, Muhammed, Biggs, Heather, Rueda, Oscar M., Chin, Suet-Feung, Dunning, Mark J., Gale, Davina, Forshew, Tim, Mahler-Araujo, Betania, Rajan, Sabrina, Humphray, Sean, Becq, Jennifer, Halsall, David, Wallis, Matthew, Bentley, David, Caldas, Carlos, and Rosenfeld, Nitzan
- Published
- 2013
- Full Text
- View/download PDF
16. Genomic landscapes of canine splenic angiosarcoma (hemangiosarcoma) contain extensive heterogeneity within and between patients.
- Author
-
Wong, Shukmei, Ehrhart, E. J., Stewart, Samuel, Zismann, Victoria, Cawley, Jacob, Halperin, Rebecca, Briones, Natalia, Richter, Keith, Sivaprakasam, Karthigayini, Perdigones, Nieves, Contente-Cuomo, Tania, Facista, Salvatore, Trent, Jeffrey M., Murtaza, Muhammed, Khanna, Chand, and Hendricks, William P. D.
- Subjects
ANGIOSARCOMA ,HETEROGENEITY ,DOGS ,GENOMICS ,CANIDAE ,MEDICAL savings accounts ,CANCER patients - Abstract
Cancer genomic heterogeneity presents significant challenges for understanding oncogenic processes and for cancer's clinical management. Variation in driver mutation frequency between patients with the same tumor type as well as within an individual patients' cancer can shape the use of mutations as diagnostic, prognostic, and predictive biomarkers. We have characterized genomic heterogeneity between and within canine splenic hemangiosarcoma (HSA), a common naturally occurring cancer in pet dogs that is similar to human angiosarcoma (AS). HSA is a clinically, physiologically, and genomically complex canine cancer that may serve as a valuable model for understanding the origin and clinical impact of cancer heterogeneity. We conducted a prospective collection of 52 splenic masses from 43 dogs (27 HSA, 15 benign masses, and 1 stromal sarcoma) presenting for emergency care with hemoperitoneum secondary to a ruptured splenic mass. Multi-platform genomic analysis included matched tumor/normal targeted sequencing panel and exome sequencing. We found candidate somatic cancer driver mutations in 14/27 (52%) HSAs. Among recurrent candidate driver mutations, TP53 was most commonly mutated (30%) followed by PIK3CA (15%), AKT1 (11%), and CDKN2AIP (11%). We also identified significant intratumoral genomic heterogeneity, consistent with a branched evolution model, through multi-region exome sequencing of three distinct tumor regions from selected primary splenic tumors. These data provide new perspectives on the genomic landscape of this veterinary cancer and suggest a cross-species value for using HSA in pet dogs as a naturally occurring model of intratumoral heterogeneity. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Evaluation of therapeutic control in a Pakistani population with hypertension
- Author
-
Saleheen, Danish, Hashmi, Saman K., Zaidi, Moazzam, Rasheed, Asif, Murtaza, Muhammed, Abbas, Adil, Nasim, Sana, Hameed, Mustafa Qadir, Shuja, Fahad, Sethi, Muhammad Jawad, Hussain, Imad, Shahid, Kamran, Khalid, Hamza, Ahmad, Usman, Frossard, Philippe M., and Ishaq, Muhammad
- Published
- 2010
- Full Text
- View/download PDF
18. Plasma metagenomic sequencing to detect and quantify bacterial DNA in ICU patients suspected of sepsis: A proof-of-principle study.
- Author
-
Kisat, Mehreen T., Odenheimer-Bergman, Ahuva, Markus, Havell, Joseph, Bellal, Srivatsan, Sridhar N., Contente-Cuomo, Tania, Khalpey, Zain, Keim, Paul, O'Keeffe, Terence, Askari, Reza, Salim, Ali, Rhee, Peter, and Murtaza, Muhammed
- Published
- 2021
- Full Text
- View/download PDF
19. The burden of stroke and transient ischemic attack in Pakistan: a community-based prevalence study
- Author
-
Akber Zainab, Akber Amna, Ali Amin, Rasheed Asif, Khan Maria, Murtaza Muhammed, Itrat Ahmed, Kamal Ayeesha, Iqbal Naved, Shoukat Sana, Majeed Farzin, and Saleheen Danish
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background The burden of cerebrovascular disease in developing countries is rising sharply. The prevalence of established risk factors of stroke is exceptionally high in Pakistan. However, there is limited data on the burden of stroke and transient ischemic attack (TIA) in South Asia. We report the first such study conducted in an urban slum of Karachi, Pakistan. Methods Individuals 35 years of age or older were invited for participation in this investigation through simple random sampling. A structured face-to-face interview was conducted using a pre-tested stroke symptom questionnaire in each participant to screen for past stroke or TIA followed by neurological examination of suspected cases. Anthropometric measurements and random blood glucose levels were recorded. Multivariable logistic regression was used to determine the association of vascular risk factors with prevalence of stroke. Results Five hundred and forty five individuals (49.4% females) participated in the study with a response rate of 90.8%. One hundred and four individuals (19.1%) were observed to have a prior stroke while TIA was found in 53 individuals (9.7%). Overall, 119 individuals (21.8% with 66.4% females) had stroke and/or TIA. Female gender, old age, raised random blood glucose level and use of chewable tobacco were significantly associated with the prevalence of cerebrovascular disease. Conclusion This is the first study demonstrating an alarmingly high life-time prevalence of cerebrovascular disease in Pakistan. Individual and public health interventions in Pakistan to increase awareness about stroke, its prevention and therapy are warranted.
- Published
- 2009
- Full Text
- View/download PDF
20. The Karachi intracranial stenosis study (KISS) Protocol: An urban multicenter case-control investigation reporting the clinical, radiologic and biochemical associations of intracranial stenosis in Pakistan
- Author
-
Makki Karim, Sheikh Niaz, Mahmood Khalid, Ahmed Naveeduddin, Khan Farrukh, Naz Sobia, Yameen Madiha, Samuel Maria, Shah Nabi, Bansari Lajpat, Waheed Shahan, Saleem Uzma, Alam Syed, Hashmat Fahad, Iqbal Naved, Murtaza Muhammed, Zaidi Moazzam, Rasheed Asif, Junaidi Babar, Taj Fawad, Kamal Ayeesha, Ahmed Muhammad, Memon Abdul, Wasay Mohammad, Syed Nadir, Khealani Bhojo, Frossard Philippe M, and Saleheen Danish
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Background Intracranial stenosis is the most common cause of stroke among Asians. It has a poor prognosis with a high rate of recurrence. No effective medical or surgical treatment modality has been developed for the treatment of stroke due to intracranial stenosis. We aim to identify risk factors and biomarkers for intracranial stenosis and to develop techniques such as use of transcranial doppler to help diagnose intracranial stenosis in a cost-effective manner. Methods/Design The Karachi Intracranial Stenosis Study (KISS) is a prospective, observational, case-control study to describe the clinical features and determine the risk factors of patients with stroke due to intracranial stenosis and compare them to those with stroke due to other etiologies as well as to unaffected individuals. We plan to recruit 200 patients with stroke due to intracranial stenosis and two control groups each of 150 matched individuals. The first set of controls will include patients with ischemic stroke that is due to other atherosclerotic mechanisms specifically lacunar and cardioembolic strokes. The second group will consist of stroke free individuals. Standardized interviews will be conducted to determine demographic, medical, social, and behavioral variables along with baseline medications. Mandatory procedures for inclusion in the study are clinical confirmation of stroke by a healthcare professional within 72 hours of onset, 12 lead electrocardiogram, and neuroimaging. In addition, lipid profile, serum glucose, creatinine and HbA1C will be measured in all participants. Ancillary tests will include carotid ultrasound, transcranial doppler and magnetic resonance or computed tomography angiogram to rule out concurrent carotid disease. Echocardiogram and other additional investigations will be performed at these centers at the discretion of the regional physicians. Discussion The results of this study will help inform locally relevant clinical guidelines and effective public health and individual interventions.
- Published
- 2009
- Full Text
- View/download PDF
21. Interaction between methadone and clarithromycin as the suspected cause of an opioid toxidrome.
- Author
-
Wallace, Blair, Edwardes, Daniel, Subbe, Christian, and Murtaza, Muhammed
- Abstract
A 40-year- old patient was admitted through the acute medical take with pleuritic chest pain and rigours. He had a medical history of opiate dependence and was receiving 60 mg of methadone once daily. He was diagnosed with a community-acquired pneumonia and treated with amoxicillin and clarithromycin. After administration of only two concomitant doses of methadone and oral clarithromycin, he developed an opioid toxidrome with type-2 respiratory failure, a decreased level of consciousness and pinpoint pupils. The patient was treated with naloxone and his symptoms improved. Retrospectively, it was suspected that an interaction between clarithromycin and methadone might have contributed to the toxidrome. Respiratory failure has not been previously prescribed for this combination of medication and is of high importance for physicians and pharmacists around the world. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. Analysis of recurrently protected genomic regions in cell-free DNA found in urine.
- Author
-
Markus, Havell, Zhao, Jun, Contente-Cuomo, Tania, Stephens, Michelle D., Raupach, Elizabeth, Odenheimer-Bergman, Ahuva, Connor, Sydney, McDonald, Bradon R., Moore, Bethine, Hutchins, Elizabeth, McGilvrey, Marissa, de la Maza, Michelina C., Van Keuren-Jensen, Kendall, Pirrotte, Patrick, Goel, Ajay, Becerra, Carlos, Von Hoff, Daniel D., Celinski, Scott A., Hingorani, Pooja, and Murtaza, Muhammed
- Subjects
CELL-free DNA ,URINE ,BASE pairs ,DNA ,NUCLEOTIDE sequencing ,URINARY organs - Abstract
Detecting cancer by urine cell-free DNA: Detection of cell-free DNA (cfDNA) in urine could be a noninvasive approach to diagnose cancer. However, urine cfDNA is very fragmented, making it difficult to use. Markus et al. analyzed fragmentation patterns in urine and plasma cfDNA using whole-genome sequencing in healthy individuals and those with cancer. Compared to cfDNA from healthy individuals, tumor-derived fragmentation patterns ending within recurrently protected regions occurred more frequently in urine. By comparing genome-wide differences in urine cfDNA fragmentation patterns, the authors could distinguish cancer samples from controls, suggesting that this approach might complement plasma cfDNA as a cancer diagnostic. Cell-free DNA (cfDNA) in urine is a promising analyte for noninvasive diagnostics. However, urine cfDNA is highly fragmented. Whether characteristics of these fragments reflect underlying genomic architecture is unknown. Here, we characterized fragmentation patterns in urine cfDNA using whole-genome sequencing. Size distribution of urine cfDNA fragments showed multiple strong peaks between 40 and 120 base pairs (bp) with a modal size of 81- and sharp 10-bp periodicity, suggesting transient protection from complete degradation. These properties were robust to preanalytical perturbations, such as at-home collection and delay in processing. Genome-wide sequencing coverage of urine cfDNA fragments revealed recurrently protected regions (RPRs) conserved across individuals, with partial overlap with nucleosome positioning maps inferred from plasma cfDNA. The ends of cfDNA fragments clustered upstream and downstream of RPRs, and nucleotide frequencies of fragment ends indicated enzymatic digestion of urine cfDNA. Compared to plasma, fragmentation patterns in urine cfDNA showed greater correlation with gene expression and chromatin accessibility in epithelial cells of the urinary tract. We determined that tumor-derived urine cfDNA exhibits a higher frequency of aberrant fragments that end within RPRs. By comparing the fraction of aberrant fragments and nucleotide frequencies of fragment ends, we identified urine samples from cancer patients with an area under the curve of 0.89. Our results revealed nonrandom genomic positioning of urine cfDNA fragments and suggested that analysis of fragmentation patterns across recurrently protected genomic loci may serve as a cancer diagnostic. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.
- Author
-
McDonald, Bradon R., Contente-Cuomo, Tania, Sammut, Stephen-John, Odenheimer-Bergman, Ahuva, Ernst, Brenda, Perdigones, Nieves, Chin, Suet-Feung, Farooq, Maria, Mejia, Rosa, Cronin, Patricia A., Anderson, Karen S., Kosiorek, Heidi E., Northfelt, Donald W., McCullough, Ann E., Patel, Bhavika K., Weitzel, Jeffrey N., Slavin, Thomas P., Caldas, Carlos, Pockaj, Barbara A., and Murtaza, Muhammed
- Subjects
CIRCULATING tumor DNA ,DNA analysis ,BREAST cancer ,CANCER treatment ,BLOOD volume - Abstract
Early detection, no time travel needed: Analysis of tumor DNA shed into a patient's circulation can provide a noninvasive means of detecting the presence of a tumor and analyzing its DNA for targetable mutations. Unfortunately, it can be difficult to detect small amounts of tumor DNA in the blood, especially in patients who have already undergone initial chemotherapy treatment. To address this problem, McDonald et al. developed a method of targeted digital sequencing (TARDIS), which is customized for each patient but can then be used to monitor the patient over time for and allow early detection of tumor recurrence. Longitudinal analysis of circulating tumor DNA (ctDNA) has shown promise for monitoring treatment response. However, most current methods lack adequate sensitivity for residual disease detection during or after completion of treatment in patients with nonmetastatic cancer. To address this gap and to improve sensitivity for minute quantities of residual tumor DNA in plasma, we have developed targeted digital sequencing (TARDIS) for multiplexed analysis of patient-specific cancer mutations. In reference samples, by simultaneously analyzing 8 to 16 known mutations, TARDIS achieved 91 and 53% sensitivity at mutant allele fractions (AFs) of 3 in 10
4 and 3 in 105 , respectively, with 96% specificity, using input DNA equivalent to a single tube of blood. We successfully analyzed up to 115 mutations per patient in 80 plasma samples from 33 women with stage I to III breast cancer. Before treatment, TARDIS detected ctDNA in all patients with 0.11% median AF. After completion of neoadjuvant therapy, ctDNA concentrations were lower in patients who achieved pathological complete response (pathCR) compared to patients with residual disease (median AFs, 0.003 and 0.017%, respectively, P = 0.0057, AUC = 0.83). In addition, patients with pathCR showed a larger decrease in ctDNA concentrations during neoadjuvant therapy. These results demonstrate high accuracy for assessment of molecular response and residual disease during neoadjuvant therapy using ctDNA analysis. TARDIS has achieved up to 100-fold improvement beyond the current limit of ctDNA detection using clinically relevant blood volumes, demonstrating that personalized ctDNA tracking could enable individualized clinical management of patients with cancer treated with curative intent. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
24. Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
- Author
-
Schwarz, Roland F, Ng, Charlotte KY, Cooke, Susanna L, Newman, Scott, Temple, Jillian, Piskorz, Anna M, Gale, Davina, Sayal, Karen, Murtaza, Muhammed, Baldwin, Peter J, Rosenfeld, Nitzan, Earl, Helena M, Sala, Evis, Jimenez-Linan, Mercedes, Parkinson, Christine A, Markowetz, Florian, Brenton, James D, Gale, Davina [0000-0002-4521-8199], Rosenfeld, Nitzan [0000-0002-2825-4788], Earl, Helena [0000-0003-1549-8094], Sala, Evis [0000-0002-5518-9360], Markowetz, Florian [0000-0002-2784-5308], Brenton, James [0000-0002-5738-6683], and Apollo - University of Cambridge Repository
- Subjects
Ovarian Neoplasms ,Genetic Variation ,DNA, Neoplasm ,Carcinoma, Ovarian Epithelial ,Middle Aged ,Disease-Free Survival ,Drug Resistance, Neoplasm ,Medicine ,Humans ,Female ,Neoplasms, Glandular and Epithelial ,Algorithms ,Alleles ,Phylogeny ,Research Article ,Aged ,Platinum - Abstract
Background The major clinical challenge in the treatment of high-grade serous ovarian cancer (HGSOC) is the development of progressive resistance to platinum-based chemotherapy. The objective of this study was to determine whether intra-tumour genetic heterogeneity resulting from clonal evolution and the emergence of subclonal tumour populations in HGSOC was associated with the development of resistant disease. Methods and Findings Evolutionary inference and phylogenetic quantification of heterogeneity was performed using the MEDICC algorithm on high-resolution whole genome copy number profiles and selected genome-wide sequencing of 135 spatially and temporally separated samples from 14 patients with HGSOC who received platinum-based chemotherapy. Samples were obtained from the clinical CTCR-OV03/04 studies, and patients were enrolled between 20 July 2007 and 22 October 2009. Median follow-up of the cohort was 31 mo (interquartile range 22–46 mo), censored after 26 October 2013. Outcome measures were overall survival (OS) and progression-free survival (PFS). There were marked differences in the degree of clonal expansion (CE) between patients (median 0.74, interquartile range 0.66–1.15), and dichotimization by median CE showed worse survival in CE-high cases (PFS 12.7 versus 10.1 mo, p = 0.009; OS 42.6 versus 23.5 mo, p = 0.003). Bootstrap analysis with resampling showed that the 95% confidence intervals for the hazard ratios for PFS and OS in the CE-high group were greater than 1.0. These data support a relationship between heterogeneity and survival but do not precisely determine its effect size. Relapsed tissue was available for two patients in the CE-high group, and phylogenetic analysis showed that the prevalent clonal population at clinical recurrence arose from early divergence events. A subclonal population marked by a NF1 deletion showed a progressive increase in tumour allele fraction during chemotherapy. Conclusions This study demonstrates that quantitative measures of intra-tumour heterogeneity may have predictive value for survival after chemotherapy treatment in HGSOC. Subclonal tumour populations are present in pre-treatment biopsies in HGSOC and can undergo expansion during chemotherapy, causing clinical relapse., In this study, James Brenton and colleagues demonstrate that quantitative measures of intratumoural heterogeneity may have predictive value for survival after chemotherapy treatment in high-grade serous ovarian cancer., Editors’ Summary Background Every year, nearly 250,000 women develop ovarian cancer, and about 150,000 die from the disease. Ovarian cancer occurs when a cell on the surface of the ovaries (two small organs in the pelvis that produce eggs) or in the Fallopian tubes (which connect the ovaries to the womb) acquires genetic changes (mutations) that allow it to grow uncontrollably and to spread around the body (metastasize). For women whose ovarian cancer is diagnosed when it is confined to its site of origin, the outlook is good. About 90% of these women survive for at least five years. However, ovarian cancer is rarely diagnosed this early. Usually, by the time the cancer causes symptoms (often only vague abdominal pains and mild digestive disturbances), it has spread into the peritoneal cavity (the space around the gut, stomach, and liver) or has metastasized to distant organs. Patients with advanced ovarian cancer are treated with a combination of surgery and platinum-based chemotherapy, but only a quarter of such women are still alive five years after diagnosis, and the overall five-year survival rate for ovarian cancer is less than 50%. Why Was This Study Done? The major clinical challenge in the treatment of high-grade serous ovarian cancer (HGSOC; the most common type of ovarian cancer) is the development of resistance to platinum-based chemotherapy. If we knew how this resistance develops, it might be possible to improve the treatment of HGSOC. Tumors are thought to arise from a single mutated cell that accumulates additional mutations as it grows and divides. This process results in the formation of subpopulations of tumor cells, each with a different set of mutations. Experts think that this “intra-tumor heterogeneity” gives rise to tumor subclones that possess an evolutionary advantage over other subclones (they might, for example, grow faster or be resistant to chemotherapy) and that eventually dominate the tumor (“clonal expansion”). Here, the researchers investigate whether clonal evolution and the emergence of subclonal tumor populations explains the development of chemotherapy-resistant HGSOC by undertaking evolutionary inference and phylogenetic quantification of the heterogeneity of samples taken from women with HGSOC at different times and from different places in their body. Evolutionary inference and phylogenetic quantification are analytical approaches that can be used to reconstruct the evolutionary history (“family tree”) of a tumor. What Did the Researchers Do and Find? The researchers used an algorithm (a step-by-step procedure for data processing) called MEDICC to analyze detailed genetic data obtained from 135 spatially and temporally separated samples taken from 14 patients with HGSOC who had received platinum-based chemotherapy. The researchers report that there were marked differences in the degree of clonal expansion among the patients. When they split the patients into two groups based on the degree of clonal expansion in their tumors (CE-high and CE-low), patients with tumors classified as CE-high had a shorter progression-free survival time than patients with tumors classified as CE-high (10.1 months compared to 12.7 months) and a shorter overall survival time (23.5 months compared to 42.6 months). Moreover, a type of statistical analysis called bootstrap analysis, which tests for the robustness of the result, indicated that having CE-high tumors was likely to increase a patient’s risk of a poor outcome. Finally, phylogenetic analysis of samples taken from two patients before and after relapse and analysis of a NF1 deletion (NF1 encodes neurofibromin 1, a tumor suppressor protein that prevents uncontrolled cell growth; NF1 is frequently mutated in HGSOC) indicated that a resistant subclonal population was already present in the patients’ tumors before treatment began. What Do These Findings Mean? These findings show that clonal expansion occurs between diagnosis and relapse in HGSOC, that there are marked differences in the degree of clonal expansion among patients, and that a high degree of clonal expansion may have a negative effect on survival. The accuracy of these findings is limited by the small number of patients included in the study, and it is likely that the analyses reported here overestimate the effect of clonal expansion on patient outcomes. Nevertheless, the researchers suggest that, provided larger patient studies yield similar results, quantitative measures of intra-tumor heterogeneity might be useful as patient-specific prognostic markers in HGSOC. That is, measures of intra-tumor heterogeneity might eventually help clinicians to predict which of their patients with ovarian cancer are likely to have the best outcomes after platinum-based chemotherapy. Additional Information Please access these websites via the online version of this summary at http://dx.doi.org/10.1371/journal.pmed.1001789. The US National Cancer Institute provides information about cancer and how it develops (in English and Spanish), including detailed information about ovarian cancer Cancer Research UK, a not-for-profit organization, provides general information about cancer and how it develops, and detailed information about ovarian cancer The UK National Health Service Choices website has information and personal stories about ovarian cancer The not-for-profit organization Healthtalk.org provides personal stories about dealing with ovarian cancer; Eyes on the Prize, an online support group for women who have had cancers of the female reproductive system, also includes personal stories; the not-for-profit organization Ovarian Cancer Action also provides information, support, and personal stories about ovarian cancer Wikipedia provides information about clonal evolution in cancer, tumor heterogeneity, and phylogenetics (note that Wikipedia is a free online encyclopedia that anyone can edit; available in several languages) More information about the MEDICC algorithm is available
- Published
- 2015
25. Identification of a Circulating Mirna Diagnostic Signature in Pancreatic Ductal Adenocarcinoma
- Author
-
Carlos Becerra, Susan Tsai, Danniel V. Hoff, Takeshi Nagasaka, Shusuke Toden, Douglas B. Evans, Haiyong Han, Murtaza Muhammed, Toshiyoshi Fujiwara, Kazuhiro Yoshida, Scott Celinski, and Ajay Goel
- Subjects
Oncology ,Circulating mirnas ,medicine.medical_specialty ,Pancreatic ductal adenocarcinoma ,Hepatology ,business.industry ,Internal medicine ,Gastroenterology ,Cancer research ,Medicine ,Identification (biology) ,business - Published
- 2017
- Full Text
- View/download PDF
26. Long-tunneled versus short-tunneled external ventricular drainage: Prospective experience from a developing country.
- Author
-
Tahir, Muhammad Zubair, Sobani, Zain A., Murtaza, Muhammed, and Enam, Syed Ather
- Subjects
CEREBROSPINAL fluid ,NEUROSURGERY ,INFECTION prevention ,VASCULAR surgery ,SURGICAL complications - Abstract
Background: External ventricular drains (EVD) are commonly utilized for temporary diversion of cerebrospinal fluid (CSF). Many neurosurgeons prefer long-tunneled EVDs in their routine practice. However, it is still unclear whether this extended tunneling helps in reducing CSF infection. Keeping this in mind, we decided to compare infection rates in long-tunneled versus short-tunneled EVDs in the setting of a developing country. Materials and Methods: A prospective study of 60 patients was conducted. Consenting patients who underwent short-tunneled (Group A) or long-tunneled (Group B) EVDs between January 2008 and June 2009 were followed during the course of their inpatient care. All operational protocol was standardized during the trial. Serial samples of CSF were analyzed to detect infection. Results: Mean age of patients was 33.6 years with 32 males (53.3%). Mean duration of long-tunneled EVD was 13.4 ± 7.2 days, whereas that of short-tunneled EVD was 5.3 ± 2.7 days (P < 0.001). Three patients with long-tunneled EVD (10.0%), whereas one patient with short-tunneled EVD (3.3%) developed drain-related infections; however, this was non-significant (P = 0.301). However, patients with short-tunneled EVD got infected earlier on day 3when compared with the long-tunneled EVDs, which got infected after a mean duration of 7.3 days. The overall risk of infection for long-tunneled EVDs was 7.46 per 1,000 ventricular drainage days which was comparable to the risk of 6.33 per 1,000 ventricular drainage days seen for short-tunneled EVDs. Conclusion: Long-tunneled EVDs appear to only delay potential infections without having any effect on the actual risk of infection. Long-tunneled EVD in a resource-limited setting is technically challenging and may not yield additional benefits to the patient. However, larger and prospective studies are needed to establish the rate of infections and other complications. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
27. Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes.
- Author
-
Beaufort, Corine M., Helmijr, Jean C. A., Piskorz, Anna M., Hoogstraat, Marlous, Ruigrok-Ritstier, Kirsten, Besselink, Nicolle, Murtaza, Muhammed, van IJcken, Wilfred F. J., Heine, Anouk A. J., Smid, Marcel, Koudijs, Marco J., Brenton, James D., Berns, Els M. J. J., and Helleman, Jozien
- Subjects
OVARIAN cancer diagnosis ,CANCER cell culture ,CELL morphology ,METASTASIS ,CANCER histopathology ,GENE expression profiling - Abstract
Epithelial ovarian cancer is a highly heterogeneous disease and remains the most lethal gynaecological malignancy in the Western world. Therapeutic approaches need to account for inter-patient and intra-tumoural heterogeneity and detailed characterization of in vitro models representing the different histological and molecular ovarian cancer subtypes is critical to enable reliable preclinical testing. There are approximately 100 publicly available ovarian cancer cell lines but their cellular and molecular characteristics are largely undescribed. We have characterized 39 ovarian cancer cell lines under uniform conditions for growth characteristics, mRNA/microRNA expression, exon sequencing, drug response for clinically-relevant therapeutics and collated all available information on the original clinical features and site of origin. We tested for statistical associations between the cellular and molecular features of the lines and clinical features. Of the 39 ovarian cancer cell lines, 14 were assigned as high-grade serous, four serous-type, one low-grade serous and 20 non-serous type. Three morphological subtypes: Epithelial (n = 21), Round (n = 7) and Spindle (n = 12) were identified that showed distinct biological and molecular characteristics, including overexpression of cell movement and migration-associated genes in the Spindle subtype. Comparison with the original clinical data showed association of the spindle-like tumours with metastasis, advanced stage, suboptimal debulking and poor prognosis. In addition, the expression profiles of Spindle, Round and Epithelial morphologies clustered with the previously described C1-stromal, C5-mesenchymal and C4 ovarian subtype expression profiles respectively. Comprehensive profiling of 39 ovarian cancer cell lines under controlled, uniform conditions demonstrates clinically relevant cellular and genomic characteristics. This data provides a rational basis for selecting models to develop specific treatment approaches for histological and molecular subtypes of ovarian cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
28. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis.
- Author
-
Weaver, Jamie M J, Ross-Innes, Caryn S, Shannon, Nicholas, Lynch, Andy G, Forshew, Tim, Barbera, Mariagnese, Murtaza, Muhammed, Ong, Chin-Ann J, Lao-Sirieix, Pierre, Dunning, Mark J, Smith, Laura, Smith, Mike L, Anderson, Charlotte L, Carvalho, Benilton, O'Donovan, Maria, Underwood, Timothy J, May, Andrew P, Grehan, Nicola, Hardwick, Richard, and Davies, Jim
- Subjects
ESOPHAGEAL cancer ,ESOPHAGUS diseases ,BARRETT'S esophagus ,CARCINOGENESIS ,NUCLEOTIDE sequencing ,GENETICS - Abstract
Cancer genome sequencing studies have identified numerous driver genes, but the relative timing of mutations in carcinogenesis remains unclear. The gradual progression from premalignant Barrett's esophagus to esophageal adenocarcinoma (EAC) provides an ideal model to study the ordering of somatic mutations. We identified recurrently mutated genes and assessed clonal structure using whole-genome sequencing and amplicon resequencing of 112 EACs. We next screened a cohort of 109 biopsies from 2 key transition points in the development of malignancy: benign metaplastic never-dysplastic Barrett's esophagus (NDBE; n = 66) and high-grade dysplasia (HGD; n = 43). Unexpectedly, the majority of recurrently mutated genes in EAC were also mutated in NDBE. Only TP53 and SMAD4 mutations occurred in a stage-specific manner, confined to HGD and EAC, respectively. Finally, we applied this knowledge to identify high-risk Barrett's esophagus in a new non-endoscopic test. In conclusion, mutations in EAC driver genes generally occur exceptionally early in disease development with profound implications for diagnostic and therapeutic strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
29. Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
- Author
-
Gossage, Lucy, Murtaza, Muhammed, Slatter, Andrew F., Lichtenstein, Conrad P., Warren, Anne, Haynes, Beverley, Marass, Francesco, Roberts, Ian, Shanahan, Susan J., Claas, Andreas, Dunham, Andrew, May, Andrew P., Rosenfeld, Nitzan, Forshew, Tim, and Eisen, Tim
- Published
- 2014
- Full Text
- View/download PDF
30. Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA.
- Author
-
Forshew, Tim, Murtaza, Muhammed, Parkinson, Christine, Gale, Davina, Tsui, Dana W. Y., Kaper, Fiona, Dawson, Sarah-Jane, Piskorz, Anna M., Jimenez-Linan, Mercedes, Bentley, David, Hadfield, James, May, Andrew P., Caldas, Carlos, Brenton, James D., and Rosenfeld, Nitzan
- Published
- 2012
- Full Text
- View/download PDF
31. Genetic Determinants of Major Blood Lipids in Pakistanis Compared With Europeans.
- Author
-
Saleheen, Danish, Soranzo, Nicole, Rasheed, Asif, Scharnagl, Hubert, Gwilliam, Rhian, Alexander, Myriam, Inouye, Michael, Zaidi, Moazzam, Potter, Simon, Haycock, Philip, Bumpstead, Suzanna, Kaptoge, Stephen, Angelantonio, Emanuele Di, Sarwar, Nadeem, Hunt, Sarah E., Sheikh, Nasir, Shah, Nabi, Samuel, Maria, Haider, Shajjia Razi, and Murtaza, Muhammed
- Subjects
GENETIC sex determination ,BLOOD lipids ,GENES ,EUROPEANS ,PAKISTANIS ,GERMANS - Abstract
The article discusses research on the lower genetic determinants in the major blood lipids among Pakistanis in comparison with those of Europeans. Assessed were variants across 2000 genes in 3200 Pakistanis using the same gene array and lipid assays used with those of 2450 Germans. Findings showed that there were several lipid-related genetic variants present among Pakistanis and Europeans while there is a difference in allelic frequencies and effect of sizes of lipid-related variants between Europeans and Pakistanis.
- Published
- 2010
- Full Text
- View/download PDF
32. Classification and Clinical Features of Headache Disorders in Pakistan: A Retrospective Review of Clinical Data.
- Author
-
Murtaza, Muhammed, Kisat, Mehreen, Daniel, Haroon, and Sonawalla, Aziz B.
- Subjects
- *
DISEASES , *HEADACHE , *PUBLIC health , *MIGRAINE , *EPIDEMIOLOGY , *CLUSTER headache , *FAMILY history (Medicine) - Abstract
Background: Morbidity associated with primary headache disorders is a major public health problem with an overall prevalence of 46%. Tension-type headache and migraine are the two most prevalent causes. However, headache has not been sufficiently studied as a cause of morbidity in the developing world. Literature on prevalence and classification of these disorders in South Asia is scarce. The aim of this study is to describe the classification and clinical features of headache patients who seek medical advice in Pakistan. Methods and Results: Medical records of 255 consecutive patients who presented to a headache clinic at a tertiary care hospital were reviewed. Demographic details, onset and lifetime duration of illness, pattern of headache, associated features and family history were recorded. International Classification of Headache Disorders version 2 was applied. 66% of all patients were women and 81% of them were between 16 and 49 years of age. Migraine was the most common disorder (206 patients) followed by tension-type headache (58 patients), medication-overuse headache (6 patients) and cluster headache (4 patients). Chronic daily headache was seen in 99 patients. Patients with tension-type headache suffered from more frequent episodes of headache than patients with migraine (p<0.001). Duration of each headache episode was higher in women with menstrually related migraine (p = 0.015). Median age at presentation and at onset was lower in patients with migraine who reported a first-degree family history of the disease (p = 0.003 and p<0.001 respectively). Conclusions/Significance: Patients who seek medical advice for headache in Pakistan are usually in their most productive ages. Migraine and tension-type headache are the most common clinical presentations of headache. Onset of migraine is earlier in patients with first-degree family history. Menstrually related migraine affects women with headache episodes of longer duration than other patients and it warrants special therapeutic consideration. Follow-up studies to describe epidemiology and burden of headache in Pakistan are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
33. Use and Impact of ICT on SMEs in Oman.
- Author
-
Ashrafi, Rafi and Murtaza, Muhammed
- Subjects
INFORMATION technology ,INFORMATION resources management ,SMALL business ,BUSINESS - Abstract
This paper presents the results of an exploratory study carried out to learn about the use and impact of Information and Communication Technologies (ICT) on Small and Medium Sized Enterprises (SMEs) in Oman. The study investigates ICT infrastructure, software used, driver for ICT investment, perceptions about business benefits of ICT and outsourcing trends of SMEs. The study provides an insight on the barriers for the adoption of ICT. Data on these aspects of ICT was collected from 51 SMEs through a survey instrument. The results of the study show that only a small number of SMEs in Oman are aware of the benefits of ICT adoption. The main driving forces for ICT investment are to provide better and faster customer service and to stay ahead of the competition. A majority of surveyed SMEs have reported a positive performance and other benefits by utilizing ICT in their businesses. Majority of SMEs outsource most of their ICT activities. Lack of internal capabilities, high cost of ICT and lack of information about suitable ICT solutions and implementation were some of the major barriers in adopting ICT. These findings are consistent with other studies e.g. (Harindranath et al 2008). There is a need for more focus and concerted efforts on increasing awareness among SMEs on the benefits of ICT adoption. The results of the study recognize the need for more training facilities in ICT for SMEs, measures to provide ICT products and services at an affordable cost, and availability of free professional advice and consulting at reasonable cost to SMEs. Our findings therefore have important implication for policy aimed at ICT adoption and use by SMEs. The findings of this research will provide a foundation for future research and will help policy makers in understanding the current state of affairs of the usage and impact of ICT on SMEs in Oman. [ABSTRACT FROM AUTHOR]
- Published
- 2008
34. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
- Author
-
Murtaza, Muhammed, Dawson, Sarah-Jane, Pogrebniak, Katherine, Rueda, Oscar M., Provenzano, Elena, Grant, John, Chin, Suet-Feung, Tsui, Dana W. Y., Marass, Francesco, Gale, Davina, Ali, H. Raza, Shah, Pankti, Contente-Cuomo, Tania, Farahani, Hossein, Shumansky, Karey, Kingsbury, Zoya, Humphray, Sean, Bentley, David, Shah, Sohrab P., and Wallis, Matthew
- Published
- 2015
- Full Text
- View/download PDF
35. Circulating tumor DNA as an early cancer detection tool.
- Author
-
Campos-Carrillo, Andrea, Weitzel, Jeffrey N., Sahoo, Prativa, Rockne, Russell, Mokhnatkin, Janet V., Murtaza, Muhammed, Gray, Stacy W., Goetz, Laura, Goel, Ajay, Schork, Nicholas, and Slavin, Thomas P.
- Subjects
- *
CIRCULATING tumor DNA , *EARLY detection of cancer , *DNA copy number variations , *BIOMARKERS - Abstract
Circulating tumor DNA holds substantial promise as an early detection biomarker, particularly for cancers that do not have currently accepted screening methodologies, such as ovarian, pancreatic, and gastric cancers. Many features intrinsic to ctDNA analysis may be leveraged to enhance its use as an early cancer detection biomarker: including ctDNA fragment lengths, DNA copy number variations, and associated patient phenotypic information. Furthermore, ctDNA testing may be synergistically used with other multi-omic biomarkers to enhance early detection. For instance, assays may incorporate early detection proteins (i.e., CA-125), epigenetic markers, circulating tumor RNA, nucleosomes, exosomes, and associated immune markers. Many companies are currently competing to develop a marketable early cancer detection test that leverages ctDNA. Although some hurdles (like early stage disease assay accuracy, high implementation costs, confounding from clonal hematopoiesis, and lack of clinical utility studies) need to be addressed before integration into healthcare, ctDNA assays hold substantial potential as an early cancer screening test. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.